As the U.S. stock market experiences a downturn with the S&P 500 declining for a fourth consecutive day, investors are keenly focused on upcoming signals from Federal Reserve Chair Jerome Powell regarding interest rates. In such fluctuating market conditions, penny stocks—often representing smaller or less-established companies—remain an intriguing investment area due to their potential for substantial growth. By identifying those with strong financial foundations and promising growth trajectories, investors can uncover opportunities that might offer both stability and upside potential amidst broader market volatility.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Rewards & Risks |
| Waterdrop (WDH) | $1.78 | $661.84M | ✅ 4 ⚠️ 0 View Analysis > |
| CuriosityStream (CURI) | $4.26 | $234.62M | ✅ 4 ⚠️ 2 View Analysis > |
| WM Technology (MAPS) | $1.06 | $178.87M | ✅ 4 ⚠️ 1 View Analysis > |
| Performance Shipping (PSHG) | $2.05 | $23M | ✅ 4 ⚠️ 2 View Analysis > |
| Tuniu (TOUR) | $0.9326 | $92.9M | ✅ 3 ⚠️ 2 View Analysis > |
| Table Trac (TBTC) | $4.78 | $22.9M | ✅ 2 ⚠️ 2 View Analysis > |
| BAB (BABB) | $0.936425 | $6.9M | ✅ 2 ⚠️ 3 View Analysis > |
| Lifetime Brands (LCUT) | $3.77 | $86.32M | ✅ 3 ⚠️ 3 View Analysis > |
| Resources Connection (RGP) | $4.64 | $157.36M | ✅ 3 ⚠️ 1 View Analysis > |
| TETRA Technologies (TTI) | $4.11 | $541.12M | ✅ 3 ⚠️ 2 View Analysis > |
Click here to see the full list of 392 stocks from our US Penny Stocks screener.
Underneath we present a selection of stocks filtered out by our screen.
Adagene (ADAG)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Adagene Inc. is a clinical-stage biotechnology company focused on the research, development, and production of monoclonal antibody drugs for cancer treatment in China, with a market cap of $92.38 million.
Operations: Adagene Inc. has not reported any specific revenue segments.
Market Cap: $92.38M
Adagene Inc., a clinical-stage biotechnology company, is currently pre-revenue with earnings results indicating a net loss of US$13.48 million for the first half of 2025. Despite this, the company has demonstrated progress in its clinical development, notably receiving FDA feedback on its ADG126 trials and announcing a partnership with ConjugateBio Inc. Adagene's cash runway appears sufficient for over a year, supported by recent private placements totaling US$25 million. While highly volatile and unprofitable, Adagene has managed to reduce losses over five years and maintains more cash than total debt.
- Dive into the specifics of Adagene here with our thorough balance sheet health report.
- Examine Adagene's earnings growth report to understand how analysts expect it to perform.
Vanda Pharmaceuticals (VNDA)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Vanda Pharmaceuticals Inc. is a biopharmaceutical company that develops and commercializes therapies for high unmet medical needs globally, with a market cap of $267.67 million.
Operations: The company generates revenue from its Biotechnology (Startups) segment amounting to $203.47 million.
Market Cap: $267.67M
Vanda Pharmaceuticals, with a market cap of US$267.67 million, reported second-quarter revenue of US$52.59 million, showing modest growth from the previous year. Despite this, the company remains unprofitable with a net loss widening to US$27.21 million for the quarter. Vanda is debt-free and has short-term assets of US$394.9 million exceeding both its short and long-term liabilities, indicating strong financial stability despite ongoing losses. The company reiterated its 2025 revenue guidance between US$210 million and US$250 million and is advancing clinical trials for rare diseases like CMT2S, showcasing potential in niche therapeutic areas.
- Get an in-depth perspective on Vanda Pharmaceuticals' performance by reading our balance sheet health report here.
- Gain insights into Vanda Pharmaceuticals' future direction by reviewing our growth report.
Elite Pharmaceuticals (ELTP)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, and selling oral controlled-release and generic pharmaceuticals, with a market cap of $610.45 million.
Operations: The company generates revenue primarily from its Abbreviated New Drug Applications (ANDA) segment, which amounts to $105.45 million.
Market Cap: $610.45M
Elite Pharmaceuticals, Inc., with a market cap of US$610.45 million, reported first-quarter revenue of US$40.21 million, more than doubling from the previous year. However, the company is currently unprofitable with a net loss of US$5.88 million for the quarter and has seen its losses increase over five years at 13.3% annually. Despite this, Elite's financial position shows resilience; short-term assets exceed both short and long-term liabilities significantly, and its debt is well-covered by operating cash flow. The management team is experienced with an average tenure exceeding 11 years but faces challenges like high share price volatility and insider selling activity recently.
- Click here to discover the nuances of Elite Pharmaceuticals with our detailed analytical financial health report.
- Understand Elite Pharmaceuticals' track record by examining our performance history report.
Seize The Opportunity
- Unlock more gems! Our US Penny Stocks screener has unearthed 389 more companies for you to explore.Click here to unveil our expertly curated list of 392 US Penny Stocks.
- Looking For Alternative Opportunities? Uncover 13 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Vanda Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com